Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 3, 2006, Pages 617-633

  Landolfi, Raffaele ^a   Cipriani, Maria Celeste ^a   Novarese, Linda ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

aspirin; myeloproliferative disorders; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; INTERFERON; PLACEBO; VON WILLEBRAND FACTOR;

AGE; ARTERY THROMBOSIS; BLEEDING; BLEEDING TENDENCY; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CLONAL VARIATION; DRUG CONTRAINDICATION; DRUG MECHANISM; ERYTHROCYTOSIS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE AVAILABILITY; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LEUKEMIA; LEUKOCYTE; LOW DRUG DOSE; MEDICAL RESEARCH; MICROCIRCULATION; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; RARE DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN BLEEDING; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; VON WILLEBRAND DISEASE;

HEMORRHAGE; HUMANS; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 33745002747     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.07.011     Document Type: Review

References (72)

1. Schafer A.I. Bleeding and thrombosis in myeloproliferative disorders. Blood. 64 (1984) 1-12
2. Landolfi R. Rocca B & Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Crit Rev Oncol Ematol. 20 (1995) 203-222
3. Elliott M.A., and Tefferi A. Thrombosis and haemorrage in polycythemia vera and essential thrombocythemia. Br J Haematol. 128 (2004) 275-290
4. Gruppo Italiano Studio Policitemia. Polycytemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
5. Michiels J.J., Abels J., Steketee J., Van Vliet H.H., et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 102 (1985) 466-471
6. Michiels J.J. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism-thesis. Rotterdam, 1981. Semin Thromb Haemost. 23 (1997) 335-338
7. Van Genderen P.J., Michiels J.J., Van Strik R., Lindemans J., et al. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 73 (1995) 210-214
8. Van Genderen P.J., Mulder P.G., Waleboer M., Van De Moesdijk D., et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol. 97 (1997) 179-184
9. Kurzrock R & Cohen PR. Erythromelalgia: review of clinical characteristics and pathophysiology. Am J Med. 1991;91:416-422.
10. Zucker S & Mielke CH. Classification of thrombocytosis based on platelet function test: correlation with hemorrhagic and thrombotic complications. J Lab Clin Med. 1972;80:385-394.
11. Michiels J.J., and Koudstaal P. Mulder A & Van Vliet HH. Transient neurological and ocular manifestations in primary thrombocythemia. Neurology. 43 (1993) 1107-1110
12. Schafer A.L., and Kroll M.H. Non-atheromatous arterial thrombosis. Annu Rew Med. 44 (1993) 155-170
13. Scheffer M.G., Michiels J.J., Simoons M.L., and Roeland J.R.T.C. Thrombocythaemia and coronary artery disease. Am Heart J. 122 (1991) 573-576
14. Myers T.J., Steinberg W.M., and Rickles F.R. Polycythemia vera and mesenteric arterial thrombosis. Arch Intern Med. 139 (1979) 695-698
15. Singer G. Migrating emboli of retinal arteries in thrombocythemia. Br J Ophtalmol. 53 (1969) 279-281
16. Strassman I., Silverston B.Z., Seelenfreund M.H., Sheer A., et al. Essential thrombocythemia: a rare case of central retinal artery occlusion. Metab Pediatr Syst Ophthalmol. 14 (1991) 18-20
17. Reisner S.A., Rinkevich D., et al. Markiewicz. Tatarrsky I. Cardiac involvement in patients with myeloproliferative disorders. Am J Med. 93 (1992) 498-504
18. Najean Y., and Mugnier P. Dresch C & Rain JD. Polycytemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 67 (1987) 285-291
19. Perea G., Remancha A., Besses C., Jimenez M., et al. Is polycythemia vera a serious disease in young adults?. Haematologica. 86 (2001) 543-544
20. Denniger M.H., Chait Y., Casadevall N., Hillaire S., et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 31 (2000) 587-591
21. Valla D., Casadevall N., Lacombe C., Varet B., et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 103 (1985) 329-334
22. Teofili L, De Stefano V, Leone G, Micalizzi P, et al. Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost. 1992 Mar 2;67(3):297-301.
23. Zwicky C., Theiler L., Zbaren K., Ischi E., and Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythemia vera. Br J Haematol. 117 (2002) 598-604
24. Tartaglia A., and Goldberg J. Berk P & Wasserman L. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 23 (1986) 172-176
25. Barbui T., and Buelli M. Cortelazzo S & Viero P. Aspirin and the risk of bleeding in patients with thrombocythemia. Am J Med. 83 (1987) 265-266
26. Wehmeier A., and Daum I. Jamin H & Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hemtol. 63 (1991) 101-106
27. Silverstein M & Minn R. Primary or hemorrhagic thrombocythemia. Arch Int Med. 1968;122:18-22.
28. Landolfi R., De Cristofano R., Castagnola M., Leone G., et al. Spontaneous deep hematomas in two patients with myelofibrosis. Evidence of platelet membrane glycoprotein modifications. Haematologica. 72 (1987) 45-48
29. Cortelazzo S., Viero P., Finazzi G., D'Emilio A., et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 8 (1990) 556-562
30. Marchioli R, Finazzi G, Landolfi R, Kutti J, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 Feb 14(Epub).
31. Besses C., Cervantes F., Pereira A., Florensa L., et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 13 (1999) 150-154
32. Jantunen R., Juvonen E., Ikkala E., Oksanen K., et al. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essentials thrombocythemia. Ann Hematol. 80 (2001) 74-78
33. Ruggeri M., Gisslinger H., Tosetto A., Rintelen C., et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 71 (2002) 1-6
34. Afshar-Kharghan VLA, Gray L, Padilla A, Borthakur G, et al. Haemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood. 2001;98:471a.
35. Amitrano L., Guardascione M.A., Ames P.R., Margaglione M., et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol. 72 (2003) 75-81
36. Dicato MA, Schroell B & Berchem GJ. V Leiden mutations, prothrombin and methylene-tetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia. Blood. 1999;94:11a°.
37. Faurschou M., Nielsen O.J., Jensen M.K., and Hasselbalch H.C. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol. 65 (2000) 136140
38. Gisslinger H., Rodeghiero F., Ruggeri M., et al. Heis-Vahidi Fard N. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 105 (1999) 551555
39. Jensen M.K. de Nully Brown P. Thorsen S & Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol. 69 (2002) 185191
40. Harrison C.N., Donohoe S., Carr P., Dave M., et al. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 87 (2002) 802807
41. Galli M., and Luciani D. Bertolini G & Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 101 (2003) 18271832
42. Van Genderen P.J., and Michiels J.J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med. 23 (1994) 73-77
43. Landolfi R., Marchioli R., Kutti J., Gisslinger H., et al. Efficacy and safety of low dose aspirin in polycythemia vera. NEJM. 350 (2004) 114-124
44. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002; 324:7186.
45. Pearson T.C., and Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. Lancet. 2 (1978) 1219-1222
46. Turitto V.T., and Weiss H.J. Platelet and red cell involvement in mural thrombogenesis. Ann NY Acad Sci. 416 (1983) 363-376
47. Landolfi R., Ciabattoni G., Patrignani P., Castellana M.A., et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood. 80 (1992) 1965-1971
48. Buss D.H., Stuart J.J., and Lipscomb G.E. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol. 20 (1985) 365-372
49. Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs. ;16(suppl) 5 (1993) 183-184
50. Cortellazzo S., Finazzi G., Ruggeri M., Vestri O., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 332 (1995) 1132-1136
51. Baker R.I., and Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol. 95 (1988) 82-86
52. Balduini C.L., and Bertolino G. Noris P & Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol. 95 (1991) 82-86
53. Barbui T., Cortellazzo S., Viero P., Bassan R., et al. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clini Oncol. 19 (1983) 1593-1599
54. Wu K.K. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med. 88 (1978) 711
55. Wehmeier A., Fricke S., Scharf R.E., and Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol. 45 (1990) 191197
56. Rocca B., Ciabattoni G., Tartaglione R., Cortelazzo S., et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 74 (1995) 12251230
57. Kaywin P., McDonough M., Insel P.A., and Shattil S.J. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med. 299 (1978) 505509
58. Jensen M.K. de Nully Brown P. Lund BV, Nielsen OJ & Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 110 (2000) 116124
59. Budde U., Schaefer G., Mueller N., Egli H., et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood. 64 (1984) 981-985
60. Budde U., Schart R.E., Franke P., Hartmann-Budde K., et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 82 (1993) 1749-1757
61. Budde U & Van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425-431.
62. Furlan M. Robles R & Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 87 (1996) 42234234
63. Levy G.G., Nichols W.C., Lian E.C., Foroud T., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413 (2001) 488-494
64. Van Genderen P.J., Prins F.J., Lucas I.S., van de Moesdijk D., et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol. 99 (1997) 832-836
65. Falanga A., Marchetti M., Evangelista V., Vignoli A., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 96 (2000) 42614266
66. Jensen M.K. de Nully Brown P. Lund BV, Nielsen OJ & Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 66 (2001) 143151
67. Harrison C.N., Gale R.E., Machin S.J., and Linch D.C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 93 (1999) 417424
68. Chiusolo P., La Barbera E.O., Laurenti L., Piccirillo N., et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 29 (2001) 670676
69. Shih L.Y., Lin T.L., Lai C.L., Dunn P., et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 100 (2002) 1596-1601
70. Chan F.K., Ching J.Y., Hung L.C., Wong V.W., et al. Clopidogrel versus aspirin and someprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
71. Patrono C., Coller B., and FitzGerald G.A. Hirsh J &Roth G. Platelet-activ drugs: the relationship among dose, effectiveness and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 234-264
72. Harrison CN, Campbell PJ, Buck G, Wheatley K et al. Hydroxyurea compared with anagrelide in high-risk essential thromboiythemia. N Engl J Med. 2005; 353: 33-45.